# A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers

> **NCT06611345** · NA · RECRUITING · sponsor: **Jiangsu Healthy Life Innovation Medical Technology Co., Ltd** · enrollment: 60 (estimated)

## Conditions studied

- Biliary Tract Cancers (BTC)

## Interventions

- **DEVICE:** Tumor Treating Fields
- **DRUG:** Durvalumab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT06611345
- **Lead sponsor:** Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-21
- **Primary completion:** 2026-10-30
- **Final completion:** 2027-03-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06611345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06611345, "A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06611345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*